Q32 Bio (QTTB) Stock Price, News & Analysis

Company Overview

Q32 Bio Inc. is a clinical-stage biotechnology company focused on developing therapies for diseases associated with immune dysregulation. The company’s research is aimed at restoring balance in the immune system by targeting biological pathways involved in inflammation, tissue repair and immune regulation.

Q32 Bio’s lead product candidate is bempikibart, also known as ADX-914, a fully human monoclonal antibody designed to inhibit activin A signaling through the activin receptor type IIB pathway. The company has investigated bempikibart in immune-mediated and inflammatory conditions, including atopic dermatitis and alopecia areata.

The company has also developed programs involving complement pathway modulation, including ADX-097, an investigational therapy intended to selectively inhibit the complement component C3. Q32 Bio is headquartered in Waltham, Massachusetts, and advances its programs through clinical development and collaborations with research and medical institutions.

Key Stats

• Today's Range: $10.95 to $11.41
• 50-Day Range: $10.72 to $21.38
• 52-Week Range: $1.69 to $23.57
• Volume: 251,371 shs
• Average Volume: 738,213 shs
• Market Capitalization: $330.12 million
• P/E Ratio: 3.70
• Dividend Yield: N/A
• Price Target: $31.00
• Consensus Rating: Moderate Buy

Q32 Bio Stock Analysis - MarketRank™

Q32 Bio scored higher than 75% of companies evaluated by MarketBeat, and ranked 174th out of 903 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.4 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Q32 Bio has received a consensus rating of Moderate Buy. The company's average rating score is 2.86, and is based on 1 strong buy rating, 4 buy ratings, 2 hold ratings, and no sell ratings.

Upside Potential

Q32 Bio has a consensus price target of $31.00, representing about 179.3% upside from its current price of $11.10.

Amount of Analyst Coverage

Q32 Bio has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Q32 Bio are expected to decrease in the coming year, from ($1.51) to ($1.81) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Q32 Bio is 3.70, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 38.93.

Price to Earnings Ratio vs. Sector

The P/E ratio of Q32 Bio is 3.70, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 273.55.

Price to Book Value per Share Ratio

Q32 Bio has a P/B Ratio of 3.25. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

18.23% of the float of Q32 Bio has been sold short.

Short Interest Ratio / Days to Cover

Q32 Bio has a short interest ratio ("days to cover") of 9.54.

Change versus previous month

Short interest in Q32 Bio has recently increased by 13.34%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Q32 Bio does not currently pay a dividend.

Dividend Growth

Q32 Bio does not have a long track record of dividend growth.

News and Social Media

• Score: 3.6 / 5
• News Sentiment: 0.72

News Sentiment

Q32 Bio has a news sentiment score of 0.72. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 7 news articles for Q32 Bio this week, compared to 2 articles on an average week.

Search Interest

14 people have searched for QTTB on MarketBeat in the last 30 days. This is an increase of 133% compared to the previous 30 days.

MarketBeat Follows

5 people have added Q32 Bio to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 1.8 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Q32 Bio insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $275,144.00 in company stock.

Percentage Held by Insiders

34.46% of the stock of Q32 Bio is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

31.32% of the stock of Q32 Bio is held by institutions.

Company Calendar

• Last Earnings: 8/05/2026
• Today: 9/16/2026
• Next Earnings (Estimated): 11/12/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:QTTB
• Previous Symbol: NASDAQ:QTTB
• CIK: 1661998
• Web: www.q32bio.com
• Phone: (781) 999-0232
• Fax: N/A
• Employees: 22
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Q32 Bio: $31.00
• High Price Target: $40.00
• Low Price Target: $14.00
• Potential Upside/Downside: +179.6%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.86
• Research Coverage: 7 Analysts

Profitability

• EPS (Trailing Twelve Months): $3.00
• Trailing P/E Ratio: 3.70
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $29.82 million
• Net Margins: N/A
• Pretax Margin: 62.87%
• Return on Equity: 50.17%
• Return on Assets: 29.49%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 20.30
• Quick Ratio: 20.30

Sales & Book Value

• Annual Sales: $53.74 million
• Price / Sales: 6.14
• Cash Flow: $1.54 per share
• Price / Cash Flow: 7.20
• Book Value: $3.41 per share
• Price / Book: 3.25

Miscellaneous

• Outstanding Shares: 29,770,000
• Free Float: 19,511,000
• Market Cap: $330.12 million
• Optionable: N/A
• Beta: 0.21